Optimizing the beneficial health effects of exercise for diabetes: focus on the liver! - Effect of exercise on liver fat and metabolism

niversiteit Maastricht0 个研究点目标入组 114 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•All subjects:
•Age 40-70 years
•BMI 27-35 kg/m2
•Stable dietary habits
•sedentary: no participation in any kind of sports for at least 2 years
•For diabetic patients only:
•Must be on sulphonylurea or metformin therapy for at least 6 months with constant dose for at least 2 months, or on a dietary treatment for at least 6 months
•Well-controled diabetes: fasting plasma glucose concentration * 7.0 mmol/l and < 10.0 mmol/l at the time of screening.;For subjects with non-alcoholic fatty liver disease:
•Liver fat content * 5,56%
•Fasting plasma concentration must be < 7.0 mmol/l ;For control subjects:
•Liver fat content < 5,56%
•Normoglycemic according to the WHO criteria (OGTT)

•Unstable body weight (weight gain or loss > 3 kg in the past three months)
•Participation in an intensive weight-loss program or in a exercise program during
•the last year before the start of the study.
•(Low) physical activity (more than 30 minutes (low) physical activity per week)
•Active cardiovascular disease. (This will be determined by quenstionnaires and by screening on medication. Furthermore, all subjects
•will undergo a physical examination by a medical doctor).
•Chronic renal dysfunction (creatinine > 2 increased (normal values: 64-104 µmol/l))
•Use of Beta-blockers
•Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
•Haemoglobin < 7.5 mmol/l (anemia)
•Blood donor
•Use of medication know to interfere with glucose homeostasis (i.e. corticosteroids), except for diabetics
•Use of anti-trombotic medication
•Claustrophobia and metal implants (with respect to MRI)
•Abuse of drugs
•Participation in another biomedical study within 1 month before the first screening
•Alcohol abuse (> 3 units (1unit = 10 gram ethanol) per day);For diabetic patients:
•Severe diabetes which requires application of insulin or patients with diabetes-related complications;For controls:
•Liver disease or liver dysfunction (ALAT > 2.5 x increased (normal values: 5 - 60 U/L))

发起方